Kernal Biologics

kernalbio.com

Kernal Biologics is pioneering the development of mRNA therapies, specifically mRNA 2.0, which targets specific cells to produce therapeutic proteins, addressing critical issues in cancer treatment. Their innovative approach, backed by a clinically validated delivery system, enhances efficacy and tolerability compared to standard treatments. With a strong foundation from MIT and Harvard, and a team with extensive experience in the biotech sector, Kernal has received recognition from Amgen and NASA, positioning itself as a leader in the mRNA therapeutic space.